Matches in Wikidata for { <http://www.wikidata.org/entity/Q66064316> ?p ?o ?g. }
Showing items 1 to 51 of
51
with 100 items per page.
- Q66064316 description "clinical trial" @default.
- Q66064316 description "ensayu clínicu" @default.
- Q66064316 description "klinisch onderzoek" @default.
- Q66064316 description "клінічне випробування" @default.
- Q66064316 name "Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis" @default.
- Q66064316 name "Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis" @default.
- Q66064316 type Item @default.
- Q66064316 label "Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis" @default.
- Q66064316 label "Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis" @default.
- Q66064316 prefLabel "Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis" @default.
- Q66064316 prefLabel "Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis" @default.
- Q66064316 P1050 Q66064316-1D569D6B-A3CF-40F5-A5DD-F314E15293A0 @default.
- Q66064316 P1050 Q66064316-F6F30DA0-01C6-42AC-8271-EC4BCCF69DD9 @default.
- Q66064316 P1132 Q66064316-34174E0A-A4D4-46CD-B2F2-08D4EE6F68F6 @default.
- Q66064316 P1476 Q66064316-684A5074-6978-4697-B686-16197861FCA7 @default.
- Q66064316 P17 Q66064316-0DB021FB-2E69-44E3-B517-0FE8B9EA7B0D @default.
- Q66064316 P17 Q66064316-3A3013C7-C6F1-4292-BC62-5E5E3F0D3705 @default.
- Q66064316 P17 Q66064316-9AB9FB60-3653-4C56-95F8-3D2C8D1A60DA @default.
- Q66064316 P17 Q66064316-9CA9046B-7487-4F79-BF57-3ABFBE66B802 @default.
- Q66064316 P17 Q66064316-A182DF2D-DCA1-4FB8-8593-7B2DB23B409C @default.
- Q66064316 P17 Q66064316-A1871348-46E0-434F-9989-914E4AD6A4FA @default.
- Q66064316 P17 Q66064316-A2AB9E43-98EB-4749-908B-F6CAD7F510DC @default.
- Q66064316 P17 Q66064316-BD709ACB-3486-47CF-A046-B6A5AB663A08 @default.
- Q66064316 P17 Q66064316-F323E361-963C-4B0D-9A34-365D5C65AC8F @default.
- Q66064316 P2899 Q66064316-50DC1F1D-2111-438E-A2B8-62C8B464E8A3 @default.
- Q66064316 P3098 Q66064316-914E3AEC-3B4F-4526-B20B-6956D0561BAF @default.
- Q66064316 P31 Q66064316-ACB9CDBA-C41B-48EE-AC5F-200B2036AB3C @default.
- Q66064316 P580 Q66064316-23383022-08AC-4B58-AABF-DAE89F5AB925 @default.
- Q66064316 P582 Q66064316-1E847EE9-8294-4B76-91AA-0BA990987D57 @default.
- Q66064316 P6099 Q66064316-D96A4381-CF14-4EBE-9C69-9F33F0134914 @default.
- Q66064316 P8363 Q66064316-26FB32BF-5F51-4B2A-97D9-5071139AB08B @default.
- Q66064316 P1050 Q229256 @default.
- Q66064316 P1050 Q988594 @default.
- Q66064316 P1132 "+750" @default.
- Q66064316 P1476 "A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis" @default.
- Q66064316 P17 Q191 @default.
- Q66064316 P17 Q218 @default.
- Q66064316 P17 Q219 @default.
- Q66064316 P17 Q28 @default.
- Q66064316 P17 Q30 @default.
- Q66064316 P17 Q31 @default.
- Q66064316 P17 Q334 @default.
- Q66064316 P17 Q36 @default.
- Q66064316 P17 Q38 @default.
- Q66064316 P2899 "+12" @default.
- Q66064316 P3098 "NCT03989349" @default.
- Q66064316 P31 Q30612 @default.
- Q66064316 P580 "2019-06-30T00:00:00Z" @default.
- Q66064316 P582 "2021-12-31T00:00:00Z" @default.
- Q66064316 P6099 Q42824827 @default.
- Q66064316 P8363 Q78089383 @default.